Davaso (data, validation and software/solutions), Germany’s largest billing service provider, is acquired by the Iqvia Group, facilitating its entry into the digital billing process for e-prescriptions and also paper prescriptions. Davaso emerges from two former competitors, Inter-Forum, founded in 1990, and Syntela. Syntela was only founded in 2005 and had been offering verification software for pharmacies since 2008.
With the acquisition of Davaso, the U.S. group, the Iqvia Group, generates sales data from 6,000 pharmacies in Germany. Until now, Iqvia’s core business consisted primarily of data analysis on strategy and sales, and market research in the pharmacy sector accounted for 50 percent of sales. 85 percent of the pharmaceutical market was thus already covered by data, with the remainder accounted for by clinical studies.
Davaso’s retaxation business is relatively small, but feared by pharmacists. The company, which is headquartered in Leipzig, also has a total of 1,400 employees at its Taucha and Suhl sites and processes more than 50 percent of the 450 million pharmacy prescriptions per year with a billing volume of more than 22 billion euros. 450,000 digitized billing documents per day are processed at the three sites.
However, the Davaso Group has also created the technological infrastructure for e-prescription billing in cooperation with gematik, the Central Federal Association of the Health Insurance Funds, the National Association of Statutory Health Insurance Physicians and the Federal Union of German Associations of Pharmacists and has made a name for itself in this field. In addition to the retax business for pharmacies, Davaso mainly handles the billing process for receipts from cab drivers, midwives, care service providers, outpatient clinics, and providers of medical aids and remedies, which brings in 62 percent of revenues.
The acquisition of Davaso means that the U.S. group will gain access to German healthcare and billing data and thus enter the lucrative retax business.